Abstract. Osteoporosis is one of the major complications in anorexia nervosa (AN) patients. Receptor activator of nuclear factor κB ligand (RANKL) and osteoprotegerin (OPG) have been identified as important regulators of bone turnover. The objective of this study was to clarify the role of RANK-RANKL-OPG system, and their relationship with other regulators for bone metabolism in AN patients. We investigated serum levels of RANKL, OPG, and bone turnover markers of 26 Japanese young female AN patients and 7 age-matched healthy women. We measured serum levels of estradiol (E2), insulin like growth factor-I (IGF-I) and triiodothyronin (T3) from the same samples and studied their relationship with RANKL or OPG. Mean serum levels of E2, IGF-I, T3 and leptin in AN patients were significantly lower than those of controls (p<0.05). Serum levels of OPG in AN patients were significantly higher than those in controls and negatively correlated with body mass index (BMI), E2, IGF-I or leptin. Serum levels of free RANKL could not be detected except for only one healthy control in both groups. These results suggest that serum OPG levels may be increased by a compensatory mechanism for malnutrition and estrogen deficiency which induces an increase in bone resorption. FIFTY percent of new AN outpatients show a decrease in lumbar bone mineral density (BMD) [1] [2] [3] [4] [5] [6] . We have previously reported that the mechanism of osteoporosis in AN patients is both decreased bone formation and increased bone resorption due to decreased serum levels of insulin like growth factor-I (IGF-I) and estradiol (E2) [4, 5] . Receptor activator of nuclear factor κB ligand (RANKL) and osteoprotegerin (OPG) have been identified as important regulators of bone turnover [7] [8] [9] . RANKL is essential for osteoclast differentiation via its receptor located on the surface of osteoclast precursor cells. OPG is a soluble decoy receptor which inhibits osteoclast differentiation through its binding to RANKL. Estrogen negatively regulates osteoclast differentiation and proliferation via RANK-RANKL system, and increases osteoclast apoptosis. Estrogen also inhibits osteocyte apoptosis, maintains osteocyte viability, and stimulates osteoblast-like cells to produce OPG [10] [11] [12] [13] . It is reported that serum levels of RANKL and OPG increased in postmenopausal women [14, 15] . AN is accompanied with amenorrhea and demonstrates low serum levels of E2. Serum levels of OPG In AN patients have been already reported [16, 17] , but the results are controversial. The objective of this study is to clarify the role of RANK-RANKL-OPG system and their relationship with other regulators for bone metabolism in AN patients.
FIFTY percent of new AN outpatients show a decrease in lumbar bone mineral density (BMD) [1] [2] [3] [4] [5] [6] . We have previously reported that the mechanism of osteoporosis in AN patients is both decreased bone formation and increased bone resorption due to decreased serum levels of insulin like growth factor-I (IGF-I) and estradiol (E2) [4, 5] .
Receptor activator of nuclear factor κB ligand (RANKL) and osteoprotegerin (OPG) have been identified as important regulators of bone turnover [7] [8] [9] . RANKL is essential for osteoclast differentiation via its receptor located on the surface of osteoclast precursor cells. OPG is a soluble decoy receptor which inhibits osteoclast differentiation through its binding to RANKL. Estrogen negatively regulates osteoclast differentiation and proliferation via RANK-RANKL system, and increases osteoclast apoptosis. Estrogen also inhibits osteocyte apoptosis, maintains osteocyte viability, and stimulates osteoblast-like cells to produce OPG [10] [11] [12] [13] . It is reported that serum levels of RANKL and OPG increased in postmenopausal women [14, 15] . AN is accompanied with amenorrhea and demonstrates low serum levels of E2. Serum levels of OPG In AN patients have been already reported [16, 17] , but the results are controversial. The objective of this study is to clarify the role of RANK-RANKL-OPG system and their relationship with other regulators for bone metabolism in AN patients.
Materials and Methods

Subjects
The subjects of this study involved 26 Japanese female AN patients aged 23.2 ± 0.8 years (mean ± SE) (range; 16-30 years) with BMI of 13.8 ± 0.6 kg/m 2 (range ; 9.2-18.4 kg/m 2 ). All patients met the Diagnostic and Statistical Manual IV (DSM IV) criteria for AN, in addition to the criteria put forth by the Survey Committee for Eating Disorders of the Japanese Ministry of Health, Labor and Welfare. Nineteen of them were restricting type (ANR), and 7 of them were bingeeating/purging type (ANBP). None of them took any medications known to affect bone metabolism.
We also investigated 7 healthy women whose mean age was 24.6 ± 0.8 years (range, 23-29 years) and mean BMI was 21.4 ± 0.5 kg/m 2 (range, 19.0-22.5 kg/ m 2 ) ( Table 1 ). Blood was taken during the follicular phase. None of them had neither past history of metabolic bone diseases or medication with calcium, vitamin D, vitamin K or estrogen. Informed consent was obtained from all of the subjects of this study.
Methods
Blood samples were taken between 8:00 AM to 9:00 AM following a 12 hr overnight fast. The samples were centrifuged and stored at -80°C prior to analysis. We measured serum levels of RANKL and OPG by ELISA (Immundiagnostik, Bensheim, Germany). We measured free form (or fragment) of RANKL (free RANKL) as well as RANKL-OPG complex (total RANKL). We also measured serum calcium (Ca), phosphate (P), and intact-PTH (i-PTH). Bone alcaliphosphatase (BAP) and osteocalcin were measured as bone formation markers, and urine C-telopeptide of type 1 collagen (CTx) was measured as a bone resorption marker. To evaluate the nutritional states, we measured serum insulin like growth factor-I (IGF-I) and triiodothyronin (T3) from the same samples. Ca, P, i-PTH, and BAP were measured in the Department of Clinical Biochemistry of Tokyo Women's Medical University by standard laboratory methods. IGF-I, T3 and leptin were assayed by ECLIA, IRMA, and RIA (SRL, Inc., Tokyo, Japan), respectively. CTx was measured using enzyme-linked immunosorbent assays (Osteometer Bio Tech A/S, Rodover, Denmark). E2 was assayed by high sensitive RIA kit (Japan Schering Inc, Chiba, Japan). Anteroposterior bone mineral density (BMD) of lumbar spine (L2-4) was measured by dual X-ray absorptiometry (DXA) using a Hologic QDR-2000 apparatus (Hologic Inc., Walthman, MA, USA) in AN patients.
Statistical analysis
Date are expressed as mean ± S.E. Serum levels of OPG and other hormones between patients and controls are compared by non-parametric test (MannWhitney). Correlations between serum OPG and RANKL levels and other hormones are analyzed using Spearman's ranked correlation test. All statistics were calculated using SPSS software. A value of P<0.05 was considered statistically significant.
Results
The clinical profiles of AN patients and controls are shown in Table 1 . Mean BMI of the AN patients was significantly lower than controls (p<0.001). Mean serum levels of IGF-I, T3, E2 and leptin, which represent nutritional markers in AN patients, were significantly lower than those of controls (p<0.001) ( Table 2 ). There were no significant differences in clinical profiles such as age or BMI between ANR and ANBP. Mean serum levels of Ca, P, i-PTH, BAP, intact and glu-osteocalcin were decreased in both controls and AN, because bone formation markers of controls were lower than normal range. Mean urinary excretion of l CTx was significantly higher in AN patients than in controls (p<0.001). BMD and bone turnover markers, OPG and RANKL are shown in Table 3 . Mean serum level of OPG was significantly higher in AN patients than in controls (p<0.001). Serum levels of free RANKL could not be detected except for only one healthy control in both groups. Mean serum level of total RANKL was slightly higher in AN patients than that in controls, but did not reach statistically significance (p = 0.978). The relationships between serum OPG levels and BMI, serum IGF-I or serum E2 are shown in Figure 1 , 2 and 3, respectively. There were significant and negative correlations between serum OPG and BMI (r = -0.59, p<0.001), serum IGF-I (r = -0.56, p<0.001) or serum E2 (r = -0.63, p<0.001). However, serum OPG levels had no significant correlation with BMD, age, or bone metabolic markers including serum levels of BAP and osteocalcin, and urinary excretion of CTx. There was no correlation between total RANKL and other factors including OPG.
Discussion
We firstly demonstrated that serum levels of OPG in AN patients were significantly higher than those in age-matched healthy women and negatively correlated with serum levels of E2, BMI, or serum levels of IGF-I and leptin. Serum levels of RANKL in AN were not higher than in controls. BMI, serum levels of IGF-1 and leptin are nutritional parameters. Therefore, we conjecture that serum levels of OPG would be related to nutritional status as well as serum levels of E2. Serum levels of OPG and RANKL did not correlate with the duration of AN or any bone metabolic markers including BAP, osteocalcin, and CTx. There was no correlation between OPG and BMD. There were no significant differences between the types of AN. Kahl et al. reported low serum levels of OPG in patients with major depressive disorder and lifetime history of AN with low BMD [17] . By contrast, Misra et al. reported that AN have higher serum OPG values than controls, and that OPG correlates negatively with markers of nutritional status such as BMI or leptin, and z-scores of BMD [16] . However, there were no correlations between OPG and E2, IGF-1, or urinary free cortisol. We conjectured that we could find a significant negative correlation between serum OPG and E2 because we used high sensitive assay for detecting serum E2 levels. In contrast, the markers of bone turnover probably change rapidly and prior to a detectable change in BMD, hence we could not find a correlation between OPG and BMD. According to our previous study, the most important factor of osteoporosis in AN was the duration of BMI under 16 kg/m 2 , not BMD. We used commercial ELISA kits purchased from Immundiagnostik (Bensheim, Germany) to measure serum levels of OPG and RANKL. Mean values of OPG and free RANKL were surveyed using those ELISA kit in 142 healthy adults between 20 and 70 years old. OPG ranged between 0.01 and 5.32 pmol/L and free RANKL between 0.03 and 3.46 pmol/L [18] . In another study using the same kits, mean serum OPG level in healthy young women was 1.35 ± 1.02 pmol/L, and that of the young women taking oral contraceptives was 2.71 ± 1.42 pmol/L [19] . Mean levels of serum free and total RANKL in that group were 0.3 ± 0.33 pmol/l and 3.8 ± 1.82nmol/L, respectively. In our study, the mean values of OPG were higher and decreased together with reduction of BMI. We could not detect serum free RANKL in the present study. Mean serum levels of total RANKL revealed no differences between AN and controls. Data from children with and without diseases which affect bone loss showed that mean RANKL concentration is not different between the diseases [20] .
As to serum OPG levels in AN higher than those of controls, various hormones including estrogen, IGF-I, leptin and i-PTH are related to OPG and RANKL both in vitro and in vivo [10] [11] [12] [13] [21] [22] [23] [24] [25] [26] [27] . Seventeen βE2 dose-and time-dependently increase OPG mRNA and protein levels by the estrogen receptor-α (ERα) [10] [11] [12] [13] . E2 enhancement of OPG secretion by osteoblastic cells may play a major role in the antiresorptive action of E2 on bone. Crisafulli et al. have measured serum OPG and free RANKL, and also evaluated the ratio between these two factors [15] . They reported that postmenopausal women without treatment have increased levels of serum OPG and free RANKL and enhanced RANKL/OPG ratio in spite of E2 deficiency. Therefore, the increased serum levels of OPG seem to be a compensatory mechanism, but is ineffective in fully counterbalancing enhanced RANKL activity. EghbaliFatourechi et al. demonstrated that upregulation of RANKL on bone marrow cells is an important determinant of increased bone resorption induced by E2 deficiency in early postmenopausal women [14] . Despite clear changes in RANKL expression in the cells, they did not detect differences in circulating RANKL levels. This suggests that the activation of RANKL expression on the cell was not accompanied with a change in serum RANKL levels. Although the mean serum level of total RANKL in AN patients did not show statistically significant increase in the present study, serum OPG levels in AN patients were significantly higher than controls in spite of E2 deficiency, similarl to postmenopausal women.
Leptin increases OPG mRNA and protein expression in vitro [23] [24] [25] . However, in our study, there were negative correlations between serum OPG and leptin. IGF-I suppresses OPG expression dose-and time dependent manner and protein secretion in vitro and in vivo [21, 22] . IGF-I may act as a coupling factor in bone remodeling by activating both bone formation and bone resorption. In the present study, serum levels of OPG in AN patients were negatively correlated with serum IGF-I levels. It is supposed that low serum levels of IGF-1 may lead to an increase in OPG in AN patients.
In conclusion, the serum levels of OPG in AN patients were higher than those in controls, and had negative correlations with serum E2 levels or nutritional parameters, such as BMI, serum levels of IGF-I, or leptin. Serum OPG was increased in spite of low serum levels of E2 and leptin. These results suggest that serum OPG levels may be increased by a compensatory mechanism for estrogen deficiency induced by malnutrition.
